Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.33 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.33 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2396040 | 0.76 | DYRK1A (0.43) | DYRK1AKEAP1MEN1KMT2APIK3C3 | |
| SCHEMBL10830647 | 0.76 | PIK3C3 (0.35) | DYRK1AKEAP1MEN1KMT2APIK3C3 | |
| SCHEMBL20936361 | 0.76 | KEAP1 (0.36) | DYRK1AKEAP1MEN1KMT2APIK3C3 | |
| SCHEMBL16416918 | 0.76 | L3MBTL1 (0.36) | L3MBTL1DYRK1AKEAP1MEN1KMT2A | |
| SCHEMBL557100 | 0.76 | ABL1 (0.36) | TGFBR1DYRK1AKEAP1MEN1KMT2A | |
| SCHEMBL23697854 | 0.75 | PIK3C3 (0.35) | L3MBTL1DYRK1AKEAP1PIK3C3 | |
| SCHEMBL20852791 | 0.75 | SSTR4 (0.32) | L3MBTL1DYRK1AKEAP1PIK3C3 | |
| SCHEMBL13557978 | 0.75 | PIK3CD (0.37) | L3MBTL1DYRK1AKEAP1PIK3C3PIK3CD | |
| SCHEMBL15998377 | 0.75 | KEAP1 (0.33) | L3MBTL1DYRK1AKEAP1KMT2APIK3C3 | |
| SCHEMBL22726755 | 0.74 | SSTR4 (0.33) | PIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024059249-A1 | M4 ACTIVATORS/MODULATORS AND USES THEREOF | CEREVEL THERAPEUTICS, LLC (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2023230968-A1 | SHP2 INHIBITOR, AND CRYSTAL FORM THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海凌达生物医药有限公司 | 2023-12-07 | — | — | WO | disclosed |
| US-11807649-B2 | Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230265098-A1 | ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230250096-A1 | SUBSTITUTED PHENYL-1H-PYRROLO[2,3-c] PYRIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-10 | — | — | US | disclosed |
| WO-2023077259-A1 | FUSED TETRACYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2022253167-A1 | SUBSTITUTED PHENYL-1H-PYRROLO [2, 3-c] PYRIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022006386-A1 | ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2022-01-06 | — | — | WO | disclosed |
| US-20210371433-A1 | Novel Monocyclic And Bicyclic Ring System Substituted Carbanucleoside Analogues For Use As PRMT5 Inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-02 | — | — | US | disclosed |
| US-20210371416-A1 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF C-MET PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2021-12-02 | — | — | US | disclosed |
| WO-2013144737-A2 | NOVEL 3,5-DISUBSTITUED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF C-MET PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2013-10-03 | — | — | WO | disclosed |
| US-8513276-B2 | Imidazo[1,2-a]pyridine compounds for use in treating cancer | ASTEX THERAPEUTICS LIMITED (GB) | 2013-08-20 | — | — | US | disclosed |
| US-20120277212-A1 | Novel Oxime Derivatives and Their Use As Allosteric Modulators of Metabotropic Glutamate Receptors | PRESTWICK CHEMICAL, INC. (FR) | 2012-11-01 | — | — | US | disclosed |
| US-20120132899-A1 | NITROGENATED HETEROCYCLIC RING DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-20120132899-A1 | NITROGENATED HETEROCYCLIC RING DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-20100120761-A1 | Bicyclic Heterocyclic Compounds as FGFR Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100093718-A1 | Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-6914065-B2 | Imidazo[1,2-C]pyrimidine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. | 2005-07-05 | — | — | US | disclosed |
| US-20040138236-A1 | Imidazo-pyrimidine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2004-07-15 | — | — | US | disclosed |
| WO-2002038569-A1 | IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2002-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210371433-A1 | Novel Monocyclic And Bicyclic Ring System Substituted Carbanucleoside Analogues For Use As PRMT5 Inhibitors | PRMT5, PRMT1, PRMT8 | L3MBTL1 3721/4885UHRF1 611/4885TGFBR1 1962/4885 |
| US-20120132899-A1 | NITROGENATED HETEROCYCLIC RING DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME | H1-2, L1CAM, H1-0 | L3MBTL1 758/4885UHRF1 835/4885TGFBR1 576/4885 |
| US-20120277212-A1 | Novel Oxime Derivatives and Their Use As Allosteric Modulators of Metabotropic Glutamate Receptors | GRM4, GRM1, GRM2 | L3MBTL1 4381/4885UHRF1 2701/4885TGFBR1 1799/4885 |
| US-20040138236-A1 | Imidazo-pyrimidine derivatives as ligands for gaba receptors | GABRA3, GABRA2, GABRA1 | L3MBTL1 845/4885UHRF1 2686/4885TGFBR1 483/4885 |
| US-20230265098-A1 | ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ERBB2, ERBB3, CHEK2 | L3MBTL1 565/4885UHRF1 3867/4885TGFBR1 2704/4885 |
| US-20230250096-A1 | SUBSTITUTED PHENYL-1H-PYRROLO[2,3-c] PYRIDINE DERIVATIVES | MLLT1, BMI1, MEN1 | L3MBTL1 1833/4885UHRF1 2400/4885TGFBR1 3797/4885 |
| US-11807649-B2 | Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2 | ERBB2, ERBB3, BRCA1 | L3MBTL1 1283/4885UHRF1 3199/4885TGFBR1 2934/4885 |
| US-20100093718-A1 | Compounds | FGFR1, FGFR2, PDGFRB | L3MBTL1 4750/4885UHRF1 4165/4885TGFBR1 167/4885 |
| US-20100120761-A1 | Bicyclic Heterocyclic Compounds as FGFR Inhibitors | FGFR3, FGFR1, FGFR2 | L3MBTL1 3324/4885UHRF1 2178/4885TGFBR1 129/4885 |
| US-20210371416-A1 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF C-MET PROTEIN KINASES | MET, PRKCH, PRKCE | L3MBTL1 2796/4885UHRF1 2670/4885TGFBR1 1740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.